Tempest Therapeutics Inc.
TPST | NASDAQ
$0.78
+$0.01 (+0.80%)
Sep 22, 2026, 9:31 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 389K | n/a | n/a | n/a | 815K |
Gross Profit | n/a | -389K | n/a | n/a | n/a | -815K |
Operating Income | -26.58M | -42.03M | -29.16M | -34.64M | -26.99M | -19.3M |
Interest Income | 520K | 1.5M | 1.12M | 549K | 1.28K | 90K |
Pretax Income | -26.26M | -41.84M | -29.49M | -35.71M | -28.3M | -19.21M |
Net Income | -26.26M | -41.84M | -29.49M | -35.71M | -28.3M | -19.12M |
Selling & General & Admin | 13.97M | 13.55M | 11.66M | 12.11M | 9.82M | 4.09M |
Research & Development | 12.61M | 28.48M | 17.5M | 22.53M | 17.17M | 14.39M |
Other Expenses | n/a | -389K | n/a | n/a | n/a | n/a |
Operating Expenses | 26.58M | 41.64M | 29.16M | 34.64M | 26.99M | 18.48M |
Interest Expense | 207K | 1.32M | 1.45M | 1.62M | 1.28M | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 26.58M | 42.03M | 29.16M | 34.64M | 26.99M | 19.3M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 4.15M | 27.9M | 15.42M | 888K | 291K | 31.21K |
Shares Outstanding (Diluted) | 4.15M | 27.9M | 15.42M | 888.38K | 291.56K | 31.21K |
EPS (Basic) | -6.33 | -1.50 | -1.91 | -3.18 | -7.80 | -612.56 |
EPS (Diluted) | -6.33 | -1.50 | -1.91 | -3.18 | -7.80 | -612.56 |
EBITDA | -25.79M | -40.14M | -27.66M | -33.45M | -26.65M | -18.39M |
EBIT | -26.06M | -40.53M | -28.04M | -34.09M | -27.02M | -19.21M |
Depreciation & Amortization | 266K | 389K | 381K | 638K | 374K | 815K |
Add to Watchlist
Select watchlists to add or remove TPST